6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialJoo‐Yong Hahn, Jin‐Ok Jeong, Jang‐Ho Bae et al.|The Lancet|2018Cited by 372
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trialChan Joon Kim, Jong‐Seon Park, Mahn‐Won Park et al.|The Lancet|2021Cited by 202
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trialKi Hong Choi, Joo-Yong Hahn, Yong Hwan Park et al.|The Lancet|2025Cited by 86
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trialJi Woong Roh, Young Bin Song, Joo‐Yong Hahn et al.|Cardiology Journal|2021Cited by 23
Prognostic Value of Left Atrium Remodeling after Primary Percutaneous Coronary Intervention in Patients with ST Elevation Acute Myocardial InfarctionJang Hyun Cho, Myung Ho Jeong, Su Hyun Kim et al.|Journal of Korean Medical Science|2012Cited by 15